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ARTICLE
Clinical Study
Eribulin versus dacarbazine in patients with leiomyosarcoma:
subgroup analysis from a phase 3, open-label, randomised study
Jean-Yves Blay1, Patrick Schöffski2, Sebastian Bauer3, Anders Krarup-Hansen4, Charlotte Benson5, David R. D’Adamo6, Yan Jia6 and
Robert G. Maki7,8
BACKGROUND: This subgroup analysis of a phase 3 study compares outcomes for eribulin versus dacarbazine in patients with
leiomyosarcoma.
METHODS: Patients ≥18 years old with advanced liposarcoma or leiomyosarcoma, ECOG PS ≤2, and ≥2 prior treatment regimens
were randomly assigned (1:1) to eribulin mesylate (1.4 mg/m² intravenously on day 1 and day 8) or dacarbazine (either 850, 1000, or
1200 mg/m² intravenously) every 21 days until disease progression. The primary end point was OS; additional end points were
progression-free survival (PFS) and objective response rate (ORR).
RESULTS: 309 Patients with leiomyosarcoma were included (eribulin, n= 157; dacarbazine, n= 152). Median age was 57 years; 42%
of patients had uterine disease and 57% had nonuterine disease. Median OS was 12.7 versus 13.0 months for eribulin versus
dacarbazine, respectively (hazard ratio [HR]= 0.93 [95% CI 0.71–1.20]; P= 0.57). Median PFS (2.2 vs 2.6 months, HR= 1.07 [95% CI
0.84–1.38]; P= 0.58) and ORR (5% vs 7%) were similar between eribulin- and dacarbazine-treated patients. Grade ≥3 TEAEs occurred
in 69% of patients receiving eribulin and 59% of patients receiving dacarbazine.
CONCLUSIONS: Efﬁcacy of eribulin in patients with leiomyosarcoma was comparable to that of dacarbazine. Both agents had
manageable safety proﬁles.
British Journal of Cancer (2019) 120:1026–1032; https://doi.org/10.1038/s41416-019-0462-1
BACKGROUND
Soft tissue sarcomas (STSs) consist of a heterogeneous group of
mesenchymal tumours and comprise numerous histologically
distinct subtypes that affect various primary sites. As a group,
STS types are rare, with an incidence rate of 3–5 cases per
100,000 persons per year.1,2 Liposarcoma (LPS) and leiomyo-
sarcoma (LMS) are two of the more frequently observed sarcoma
subtypes, both of which are further categorised based on
distinctive clinical and pathologic features.2–4 LMS represents
~20% of STS cases and forms in smooth muscle, most often in
the branches of large veins such as the inferior vena cava, or in
the uterus.2,4
Patients with metastatic STS have a poor prognosis, with
disease-speciﬁc survival rates at 5 years of ~15%.5 For unresect-
able or metastatic disease, anthracycline-based chemotherapy is
the recommended ﬁrst-line treatment, with variations in practice
between use of doxorubicin as a single agent or in combination
with other agents (typically with olaratumab, ifosfamide, or
dacarbazine).6–8 Dacarbazine has shown single-agent activity
and improved efﬁcacy in combination with doxorubicin in
patients with LMS.9 In a randomised phase 1b/2 trial in
anthracycline-naive patients with advanced STS, the combination
of doxorubicin and olaratumab signiﬁcantly improved overall
survival (OS) compared with doxorubicin alone. Results of the
conﬁrmatory phase 3 trial are pending.10
Several treatment options, including ifosfamide, trabectedin,
and pazopanib, are available for second- or later-line therapy for
STS (excluding LPS).11–14 Although not approved for sarcoma,
gemcitabine, alone or in combination with either docetaxel or
dacarbazine, has demonstrated activity as second-line therapy in
STS and is frequently used in clinical practice.15,16 In recent years,
subtype-speciﬁc sensitivity to drugs has become more apparent
and several trials have focused on patient populations with
speciﬁc STS subtypes. Differing sensitivity between sarcoma
subtypes has been observed with other agents, for example,
myxoid round cell LPS is particularly sensitive to treatment with
trabectedin.11 Recent data suggest that there are different
molecular subtypes in LMS and that these subtypes are associated
with distinct clinical outcomes.17 This ﬁnding suggests potential
treatment of LMS using a more targeted approach.
Eribulin was approved in 2016 in the United States
and European Union for treatment of unresectable or metastatic
LPS in patients whose disease had failed to respond to
anthracycline chemotherapy.18,19
Eribulin is a structurally modiﬁed, synthetic analogue of
halichondrin B, a natural product isolated from the marine sponge
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Halichondria okadai.20 It is a nontaxane inhibitor of microtubule
dynamics, with a unique mechanism of action compared with
vinca alkaloids.20–22 In preclinical studies, eribulin affected tumour
biology, including vascular remodelling, reversal of the epithelial-
to-mesenchymal transition, induction of differentiation, and
suppression of migration and invasion.23–25
In a phase 2 study of eribulin in STS, 32% of patients with LMS
and 47% of patients with LPS met the primary end point of being
progression free at 12 weeks.26 Based on these results, eribulin
was evaluated in an international phase 3 study of patients with
unresectable or metastatic advanced LPS or LMS, in which eribulin
signiﬁcantly improved OS compared with dacarbazine in the total
study population (13.5 vs 11.5 months, hazard ratio [HR] 0.77
[0.62–0.95], P= 0.017).18 Here, we present the results of a
histology-driven analysis of the efﬁcacy and safety of eribulin in
patients with LMS, a randomised and stratiﬁed subgroup enrolled
in the phase 3 study.
METHODS
Study design and participants
The design of the phase 3, randomised, open-label study
(NCT01327885) evaluating the effects of eribulin compared to
dacarbazine in patients with advanced LPS or LMS has been
previously published.18 In brief, patients were randomly assigned
(1:1) between March 2011 and May 2013 to treatment groups and
stratiﬁed by the diagnosis of LPS or LMS, geographic region, and the
number of previous chemotherapy regimens. Eligible patients were
18 years or older and had histologically conﬁrmed LPS or LMS with
≥2 prior chemotherapy treatments for advanced disease. Entry
criteria also required radiographic evidence of disease progression
within 6 months prior to randomisation and the presence of
measurable disease according to Response Evaluation Criteria In
Solid Tumours version 1.1 (RECIST v1.1).27 The study was conducted
at 110 sites in 22 countries under the principles of good clinical
practice and the World Medical Association’s Declaration of Helsinki
(2008), and was approved by the respective institutional research
ethics boards of each participating site (see Supplementary Table 1).
All patients provided written informed consent.
Treatment
Eribulin mesylate was given at a dose of 1.4 mg/m2 intravenously
(equivalent to 1.23 mg/m2 eribulin [expressed as free base]) on
day 1 and day 8 of each 21-day cycle. Dacarbazine was given at a
dose of either 850, 1000, or 1200mg/m2 intravenously on the ﬁrst
day of every 21-day cycle. The dacarbazine starting dose was
selected by the investigator prior to randomisation based on each
patient’s clinical status and local institutional guidelines. Treat-
ment continued until disease progression, unacceptable toxicity,
or withdrawal of consent.
Tumours were assessed using computed tomography scans or
magnetic resonance imaging every 6 weeks for the ﬁrst 12 weeks
and then every 9 weeks thereafter until disease progression.
Tumour responses and progression status were determined based
on investigator review, following RECIST v1.1, except that chest
lesions could not be assessed using X-ray. Safety was assessed by
monitoring for treatment-emergent adverse events (TEAEs) and
regular evaluation of clinical laboratory test results, vital signs,
electrocardiography scans, and physical examinations.
Statistical analysis
The primary end point was OS, and secondary end points included
progression-free survival (PFS), progression-free rate at 12 weeks,
clinical beneﬁt rate (deﬁned as the proportion of patients whose
best overall response was complete response [CR], partial
response [PR], or durable stable disease [deﬁned as the proportion
of patients who experienced SD for ≥11 weeks]), pharmacoki-
netics, and safety. Exploratory end points included objective
response rate (ORR; deﬁned as the proportion of patients whose
best overall response was either CR or PR), and disease control
rate (deﬁned as the proportion of patients whose best overall
response was CR, PR, or SD). Subgroup analysis based on
histologic diagnosis, along with other baseline demographic and
disease factors, was prespeciﬁed in the study protocol. This study
was neither designed nor powered to draw deﬁnitive conclusions
on the activity of eribulin in histologic subgroups.
Table 1. Demographic, baseline, and disease characteristics of
patients with leiomyosarcoma
Characteristic Eribulin
(n= 157)
Dacarbazine
(n= 152)
Total
(N= 309)
Median age (minimum,
maximum), years
57 (28, 76) 56 (24, 77) 57 (24, 77)
Age group, n (%), years
<65 123 (78) 124 (82) 247 (80)
≥65 34 (22) 28 (18) 62 (20)
Sex, n (%)
Male 29 (18) 31 (20) 60 (19)
Female 128 (82) 121 (80) 249 (81)
Race, n (%)
White 110 (70) 117 (77) 227 (74)
African American 6 (4) 4 (3) 10 (3)
Asiana 14 (9) 12 (8) 26 (8)
Otherb 27 (17) 19 (12) 46 (15)
ECOG PS, n (%)
0 76 (48) 66 (43) 142 (46)
1 80 (51) 79 (52) 159 (52)
2 1 (1) 7 (5) 8 (3)
Histology subcategory, n (%)
Uterine 68 (43) 63 (41) 131 (42)
Nonuterine 88 (56) 89 (59) 177 (57)
Tumour grade, n (%)
High 112 (71) 113 (74) 225 (73)
Intermediate 45 (29) 37 (24) 82 (27)
Not done 0 2 (1) 2 (1)
Geographic region, n (%)
USA and Canada 62 (40) 61 (40) 123 (40)
Western Europe,
Australasia, Israel
70 (45) 68 (45) 138 (45)
Eastern Europe,
Latin America, Asia
25 (16) 23 (15) 48 (16)
Median age at diagnosis
(minimum, maximum), years
53.0 (24, 75) 52.5 (23, 75) 53.0 (23, 75)
Previous anticancer
therapy,c n (%)
0 0 0 0
1 2 (1) 1 (1) 3 (1)
2 76 (48) 70 (46) 146 (47)
3 44 (28) 44 (29) 88 (28)
4 17 (11) 25 (16) 42 (14)
>4 18 (12) 12 (8) 30 (10)
ECOG PS Eastern Cooperative Oncology Group performance status
aIncludes Japanese, Chinese, and other Asian
bIncludes American Indian or Alaskan Native, Native Hawaiian or Other
Paciﬁc Islander, other, and not applicable
cExcludes radiotherapy and surgery
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OS and PFS were estimated with the Kaplan–Meier product-
limit method, and 95% conﬁdence intervals (CIs) were constructed
using Greenwood’s formula. HRs were based on a Cox regression
model, including treatment as a covariate and stratiﬁcation factors
of geographic region and number of prior chemotherapy
regimens. P values were calculated using a two-sided stratiﬁed
log-rank test with the same stratiﬁcation factors as for HRs. Efﬁcacy
analyses were performed in the intent-to-treat population,
comprising all patients who were randomly assigned to treatment.
Safety data were summarised descriptively based on all rando-
mised patients who had received at least 1 dose of study
treatment and had at least 1 posttreatment safety evaluation.
RESULTS
Patients
This is a histology-driven subgroup analysis from a large,
prospective, randomised, phase 3 trial of eribulin in which 452
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0.0
No. of patients at risk:
Eribulin 157 134 111 95 81 63 58 44 30 22 18 10 5 1 1 0
Dacarbazine 152 131 116 97 81 64 52 34 26 21 14 8 3 0 0 0
0.2
0.4
0.6
0.8
1.0
3 6 9 12 15 18 21 24 27 30 33 36 39 42 45
Eribulin
Dacarbazine
HR (95% CI) 0.93 (0.71, 1.20)
P = 0.57
b
a
Overall 124/157 118/152 0.927 (0.714, 1.203) 12.7 13.0
LMS subcategory
Uterine
Nonuterine
58/68
66/88
47/63
71/89
1.249 (0.834, 1.872)
0.765 (0.539, 1.085)
9.4
14.4
12.3
13.2
Baseline ECOG PS
0
1 or 2
53/76
71/81
49/66
69/86
0.745 (0.493, 1.127)
1.252 (0.888, 1.765)
19.9
9.2
15.8
12.2
Sex
Female
Male
102/128
22/29
91/121
27/31
1.004 (0.748, 1.348)
0.639 (0.350, 1.165)
12.7
14.2
14.8
9.7
Geographic regiona
Region 1
Region 2
47/62
57/70
49/61
48/68
0.714 (0.467, 1.093)
1.315 (0.894, 1.934)
15.3
13.3
13.0
14.9
Region 3 20/25 21/23 0.630 (0.327, 1.211) 9.8 9.7
Number of prior regimens
for advanced STS
2
>2
63/82
61/75
58/81
60/71
1.094 (0.763, 1.569)
0.773 (0.529, 1.128)
13.8
12.6
15.3
11.5
Group/subgroup Eribulin Dacarbazine Eribulin Dacarbazine
— Events/n — Median (months)
HR (95% CI)
0.50.25 21
Favors eribulin Favors dacarbazine
Fig. 1 Kaplan–Meier curve of overall survival (a) and hazard ratios of overall survival (b) in patients with leiomyosarcoma. CI conﬁdence
interval, ECOG PS Eastern Cooperative Oncology Group performance score, HR hazard ratio (eribulin to dacarbazine), based on a Cox
regression model including treatment as a covariate and stratiﬁcation factors of geographic region and number of prior chemotherapy
regimens, LMS leiomyosarcoma, STS soft tissue sarcoma. a Region 1 = USA and Canada; Region 2 = Western Europe, Australasia, and Israel;
Region 3 = Eastern Europe, Latin America, and Asia
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patients with advanced LPS or LMS in the intent-to-treat population
(Supplementary Fig. 1) were randomly assigned to receive eribulin
(n= 228) or dacarbazine (n= 224). A total of 309 patients with LMS
were included in this analysis; 157 patients were treated with
eribulin and 152 were treated with dacarbazine (Table 1). Patients
with LMS composed 68% of the overall patient population in the
phase 3 study. Within the LMS subgroup, 131 (42%) patients had
uterine disease and 177 (57%) patients had nonuterine disease
(Table 1). Baseline demographic and disease characteristics were
generally well balanced between treatment arms.
Efﬁcacy
In patients with LMS, the median OS was 12.7 vs 13.0 months for
eribulin and dacarbazine, respectively (HR= 0.93 [95% CI
0.71–1.20]; P= 0.57) (Fig. 1a, b). HRs for OS favoured eribulin
treatment, but were not statistically different from dacarbazine
treatment, in patients with LMS who had >2 prior chemotherapy
treatments for advanced disease, had nonuterine disease, had a
baseline Eastern Cooperative Oncology Group performance status
of 0, were enrolled in geographic region 1 (North America) or
geographic region 3 (Eastern Europe, Latin America, and Asia), or
were male (Fig. 1b). Median OS for patients with uterine LMS was
9.4 versus 12.3 months for eribulin and dacarbazine, respectively,
which was not statistically signiﬁcantly different (HR= 1.25 [95%
CI 0.83–1.87]) (Fig. 1b, Supplementary Fig. 2a). For patients with
nonuterine disease, median OS was 14.4 versus 13.2 months for
eribulin and dacarbazine, respectively, again not statistically
signiﬁcantly different (HR= 0.77 [95% CI 0.54–1.09]) (Fig. 1b,
1.0
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a
HR (95% CI) 1.07 (0.83, 1.38)
P = 0.58
0.50.25 21
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Group/subgroup Eribulin Dacarbazine
— Events/n — Median (months)
HR (95% CI) Eribulin Dacarbazine
2.61.072 (0.835, 1.375)
LMS subcategory
Baseline ECOG PS
Number of prior regimens
for advanced STS
Geographic regiona
Sex
Overall
Uterine
Nonuterine
0
1 or 2
2
Region 1
Region 2
Region 3
Female
Male
>2
61/68
79/88
64/76
72/82
68/75
72/81
57/71
61/70
24/25
116/128
24/29
100/121
29/31
55/62
60/68
20/23
49/61
76/81
59/66
70/86
52/63
77/89
140/157 129/152
1.570 (1.049, 2.349)
0.857 (0.614, 1.194)
0.967 (0.663, 1.410)
1.433 (1.009, 2.037)
1.039 (0.742, 1.455)
1.112 (0.767, 1.612)
1.063 (0.705, 1.604)
1.159 (0.807, 1.665)
0.863 (0.462, 1.609)
1.312 (0.990, 1.739)
0.551 (0.298, 1.018)
1.4
2.8
2.8
1.5
2.7
2.6
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2.6
2.6
1.5
1.8
2.0
4.0
2.7
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2.5
2.0
2.6
2.7
2.6
2.6
b
2.2
Fig. 2 Kaplan–Meier curve of progression-free survival (a) and hazard ratios of progression-free survival (b) in patients with leiomyosarcoma.
CI conﬁdence interval, ECOG PS Eastern Cooperative Oncology Group performance score, HR hazard ratio (eribulin to dacarbazine), based on a
Cox regression model including treatment as a covariate and stratiﬁcation factors of geographic region and number of prior chemotherapy
regimens, LMS leiomyosarcoma, STS soft tissue sarcoma. a Region 1 = USA and Canada; Region 2 = Western Europe, Australasia, and Israel;
Region 3 = Eastern Europe, Latin America, and Asia
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Supplementary Fig. 2a). Male patients treated with eribulin had
numerically longer OS compared with male patients taking
dacarbazine (14.2 vs 9.7 months, respectively) (Fig. 1b, Supple-
mentary Fig. 3a), but this difference was not statistically
signiﬁcant.
Median PFS in patients with LMS was similar between treatment
arms (2.2 vs 2.6 months with eribulin and dacarbazine, respec-
tively, HR= 1.07 [95% CI 0.84–1.38]; P= 0.58) (Fig. 2a, b). In
patients with uterine LMS, median PFS was 1.4 vs 2.6 months for
eribulin and dacarbazine, respectively (HR= 1.57 [95% CI
1.05–2.35]) (Fig. 2b, Supplementary Fig. 2b). In patients with
nonuterine LMS, median PFS was 2.8 vs 2.6 months for eribulin
and dacarbazine, respectively; this difference was not statistically
signiﬁcant (HR= 0.86 [95% CI 0.61–1.19]) (Fig. 2b, Supplementary
Fig. 2b). Male patients treated with eribulin had numerically (but
not statistically signiﬁcantly) longer PFS compared with male
patients taking dacarbazine (4.0 vs 2.6 months, respectively)
(Fig. 2b, Supplementary Fig. 3b).
ORR was similar between eribulin-treated and dacarbazine-
treated patients (5% vs 7% respectively). The exploratory tumour
response end points, disease control rate and durable stable
disease rate (deﬁned as the proportion of patients with SD
≥11 weeks) were numerically higher in patients treated with
dacarbazine than in those receiving eribulin (57% [95% CI
48–64%] vs 52% [95% CI 44–60%] and 45% [95% CI 37–54%] vs
36% [95% CI 28–44%], respectively) (Table 2); these differences
were not statistically signiﬁcant.
Table 2. Summary of tumour responses by investigator assessment
Parameter Eribulin (n= 157) Dacarbazine (n= 152)
Best overall response
CR, n (%) 0 0
PR, n (%) 8 (5) 11 (7)
SD, n (%) 73 (47) 75 (49)
PD, n (%) 69 (44) 56 (37)
Not evaluable, n (%) 2 (1) 1 (1)
Unknown, n (%) 5 (3) 9 (6)
Objective response rate
ORR (95% CI) 5 (2, 10) 7 (4, 13)
Disease control rate
DCR (95% CI) 52 (44, 60) 57 (48, 64)
Durable stable disease rate
dSD (95% CI) 36 (28, 44) 45 (37, 54)
CI conﬁdence interval, CR complete response, DCR disease control rate
(deﬁned as proportion of PR+CR+SD), dSD durable stable disease (deﬁned
as the proportion with stable disease for ≥11 weeks), HR hazard ratio, ORR
objective response rate (deﬁned as the proportion of CR+ PR), PFS
progression-free survival, PD progressive disease, PR partial response, SD
stable disease
Table 3. Treatment-emergent adverse events ≥10% (all grades, either arm) in patients with leiomyosarcoma
TEAE category, n (%) Eribulin (n= 156) Dacarbazine (n= 152)
All grades Grade 3 Grade 4 All grades Grade 3 Grade 4
Neutropenia 72 (46) 36 (23) 25 (16) 40 (26) 16 (11) 8 (5)
Fatigue 71 (46) 6 (4) 0 63 (41) 3 (2) 0
Nausea 64 (41) 1 (1) 0 74 (49) 1 (1) 0
Alopecia 51 (33) 1 (1) 0 5 (3) 0 0
Constipation 51 (33) 2 (1) 0 41 (27) 1 (1) 0
Anaemia 49 (31) 10 (6) 2 (1) 44 (29) 15 (10) 4 (3)
Pyrexia 46 (30) 2 (1) 0 20 (13) 0 0
Asthenia 35 (22) 2 (1) 0 34 (22) 4 (3) 0
Cough 34 (22) 0 0 24 (16) 0 0
Headache 32 (21) 0 0 17 (11) 0 0
Peripheral sensory neuropathy 30 (19) 2 (1) 0 6 (4) 0 0
Vomiting 30 (19) 2 (1) 0 34 (22) 0 0
Abdominal pain 28 (18) 3 (2) 1 (1) 21 (14) 6 (4) 0
Decreased appetite 27 (17) 1 (1) 0 21 (14) 0 0
Dyspnoea 27 (17) 3 (2) 1 (1) 25 (16) 3 (2) 2 (1)
Back pain 26 (17) 2 (1) 0 23 (15) 3 (2) 0
Diarrhoea 25 (16) 0 0 22 (15) 0 0
Leukopenia 25 (16) 12 (8) 4 (3) 20 (13) 5 (3) 3 (2)
Stomatitis 22 (14) 2 (1) 0 4 (3) 1 (1) 0
Oedema peripheral 21 (14) 0 0 11 (7) 1 (1) 0
Abdominal pain, upper 17 (11) 0 0 8 (5) 1 (1) 0
Hypokalemia 17 (11) 4 (3) 0 7 (5) 2 (1) 0
Aspartate aminotransferase increased 16 (10) 1 (1) 0 5 (3) 2 (1) 0
Myalgia 16 (10) 0 0 16 (11) 0 0
Urinary tract infection 16 (10) 2 (1) 0 10 (7) 0 0
Thrombocytopenia 10 (6) 1 (1) 0 47 (31) 13 (9) 13 (9)
TEAE treatment-emergent adverse event
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Safety
In patients with LMS, the ﬁve most frequent TEAEs with eribulin were
neutropenia (46%), fatigue (46%), nausea (41%), alopecia (33%), and
constipation (33%). The ﬁve most frequent TEAEs with dacarbazine
were nausea (49%), fatigue (41%), thrombocytopenia (31%), anaemia
(29%), and constipation (27%) (Table 3). Grade ≥3 TEAEs were
reported in 69% of patients in the eribulin arm versus 59% of
patients in the dacarbazine arm. Grade ≥3 neutropenia and
leukopenia occurred more frequently in patients treated with
eribulin, whereas grade ≥3 anaemia and thrombocytopenia occurred
more frequently in patients treated with dacarbazine (Table 3).
Nonfatal serious adverse events occurred in 33% of patients in
the eribulin arm and 32% of patients in the dacarbazine arm
(Supplementary Table 2). TEAEs leading to treatment discontinua-
tion occurred in 8% of patients in the eribulin arm and 5% of
patients in the dacarbazine arm, and 16% of patients in the
dacarbazine arm required a dose reduction because of TEAEs
compared with 28% of patients in the eribulin arm (Supplemen-
tary Table 2). However, the frequency of dose interruptions was
similar between eribulin- and dacarbazine-treated patients (34%
each). A total of 10 patients in the LMS subgroup died from TEAEs,
including seven patients in the eribulin arm and three patients in
the dacarbazine arm (Supplementary Table 2). In the eribulin arm,
only a single event—neutropenic sepsis—was considered possibly
related to treatment. None of the three deaths in the dacarbazine
arm were considered by the investigators to be treatment related.
DISCUSSION
We present the results from a histology-driven subgroup analysis
of patients with LMS from a large-scale, prospective, randomised,
controlled, phase 3 study comparing the efﬁcacy and safety of
eribulin to dacarbazine in previously treated patients with
advanced STS of two histologically distinct types: LMS and
LPS.18 The study design was randomised and stratiﬁed based on
these histological subtypes; however, the study was neither
designed nor powered to draw deﬁnitive conclusions on the
activity of eribulin in histologic subgroups. The phase 3 study was
also not designed to be a noninferiority trial.
In this subgroup analysis of patients with LMS, median OS was
comparable between patients treated with eribulin versus
dacarbazine (HR= 0.93; 95% CI [0.71–1.20]). Secondary outcomes
of PFS (HR= 1.07; 95% CI [0.84–1.38]) and ORR (5% vs 7%,
respectively) were also comparable between eribulin and dacar-
bazine treatment groups. Historical data suggest that dacarbazine
is more active in LMS than in other sarcomas. In a randomised trial
of doxorubicin every 3 weeks versus weekly doxorubicin versus
doxorubicin plus dacarbazine for metastatic STS, the combination
demonstrated a signiﬁcant improvement in response rates in
patients with LMS compared with doxorubicin alone (44% vs 17%
[weekly] vs 20% [every 3 weeks], respectively).9 That trial included
99 (36%) of 275 evaluable patients with LMS. By comparison, this
phase 3 trial enrolled >300 (309/452; 68%) patients with LMS.
This subgroup analysis supports the hypothesis that treatment
outcomes for a particular sarcoma histology will differ as a
function of its primary anatomic site.2,28 In patients with
nonuterine LMS, HRs for OS and PFS favoured eribulin, whereas
in patients with uterine LMS, HRs for OS and PFS favoured
dacarbazine. However, further research is required to determine if
various primary LMS sites have molecular differences that would
suggest differential antitumor activity of eribulin between uterine
and nonuterine LMS and between male and female patients.
Emerging data suggest that there are differences in molecular
proﬁles between uterine and nonuterine LMS.17 Differing sensi-
tivity between sarcoma subtypes has been seen with other agents,
for example, myxoid round cell LPS is particularly sensitive to
treatment with trabectedin, whereas all LPS subtypes are equally
sensitive to doxorubicin.11 These results may highlight a need to
reﬁne stratiﬁcation criteria in STS trials to include not only disease
histology, but also disease site and molecular biology.
Dacarbazine and eribulin each had different TEAE proﬁles but,
overall, the toxicity proﬁles of both chemotherapy agents in
patients with LMS were manageable. Adverse events did not often
lead to study-drug discontinuation. No new safety signals were
identiﬁed, and adverse events associated with eribulin were
similar to previous ﬁndings.26
In summary, this subgroup analysis suggests that the effects of
eribulin treatment in patients with LMS are comparable to those of
dacarbazine. This contrasts with the results of a subgroup analysis
of patients with LPS, in which an OS beneﬁt of eribulin vs
dacarbazine was evident.29 Outcome heterogeneity within the
LMS subgroup may represent biologic differences in this sarcoma
subtype. To further understand unique sarcoma subtypes, future
prospective trials in STS should aim to examine treatment
outcomes as a function of histology, molecular alteration,
anatomic site, and gender. The LMS subtype encompasses
different disease types based on clinical and pathologic features,
and future research should beneﬁt from additional stratiﬁcation
criteria. Such research may contribute to further improvement in
outcomes for patients with LMS.
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